

**MTN 042 - DELIVER: A Phase 3b Safety Study of the Dapivirine Ring and PrEP in Pregnant Women
Data as of December 1, 2025**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site - Infants Cohort 1

| | Malawi Blantyre | SA Shandukani | Uganda Kampala | Zimbabwe Zengeza | All Sites |
|--|----------------------------|--------------------------|---------------------------|-----------------------------|------------------|
| Participants Enrolled | 27 | 40 | 44 | 36 | 147 |
| 1. Physical Exam Required and Expected | 104 | 131 | 170 | 144 | 549 |
| Completed | 104 (100.0%) | 131 (100.0%) | 170 (100.0%) | 144 (100.0%) | 549 (100.0%) |
| 2. Creatinine Required and Expected | 52 | 64 | 85 | 72 | 273 |
| Completed | 48 (92.3%) | 63 (98.4%) | 85 (100.0%) | 72 (100.0%) | 268 (98.2%) |
| Not Completed | 4 (7.7%) | 1 (1.6%) | 0 (0.0%) | 0 (0.0%) | 5 (1.8%) |
| 3. Dried Blood Spot for TFV-DP and FTC-TP drug levels Required and Expected (Truvada group only) | 8 | 12 | 14 | 11 | 45 |
| Completed | 8 (100.0%) | 11 (91.7%) | 14 (100.0%) | 11 (100.0%) | 44 (97.8%) |
| Not Completed | 0 (0.0%) | 1 (8.3%) | 0 (0.0%) | 0 (0.0%) | 1 (2.2%) |
| 4. Plasma for DPV Drug levels Required and Expected (DPV group only) | 18 | 25 | 29 | 25 | 97 |
| Completed | 16 (88.9%) | 25 (100.0%) | 29 (100.0%) | 25 (100.0%) | 95 (97.9%) |
| Not Completed | 2 (11.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (2.1%) |

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 042 - DELIVER: A Phase 3b Safety Study of the Dapivirine Ring and PrEP in Pregnant Women
Data as of December 1, 2025**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site - Infants Cohort 2

| | Malawi Blantyre | SA Shandukani | Uganda Kampala | Zimbabwe Zengeza | All Sites |
|--|----------------------------|--------------------------|---------------------------|-----------------------------|------------------|
| Participants Enrolled | 39 | 26 | 42 | 47 | 154 |
| 1. Physical Exam Required and Expected | 152 | 80 | 165 | 182 | 579 |
| Completed | 152 (100.0%) | 80 (100.0%) | 165 (100.0%) | 182 (100.0%) | 579 (100.0%) |
| 2. Creatinine Required and Expected | 76 | 47 | 83 | 94 | 300 |
| Completed | 76 (100.0%) | 45 (95.7%) | 83 (100.0%) | 94 (100.0%) | 298 (99.3%) |
| Not Completed | 0 (0.0%) | 2 (4.3%) | 0 (0.0%) | 0 (0.0%) | 2 (0.7%) |
| 3. Dried Blood Spot for TFV-DP and FTC-TP drug levels Required and Expected (Truvada group only) | 13 | 7 | 15 | 15 | 50 |
| Completed | 13 (100.0%) | 7 (100.0%) | 15 (100.0%) | 15 (100.0%) | 50 (100.0%) |
| 4. Plasma for DPV Drug levels Required and Expected (DPV group only) | 25 | 17 | 27 | 32 | 101 |
| Completed | 23 (92.0%) | 16 (94.1%) | 27 (100.0%) | 32 (100.0%) | 98 (97.0%) |
| Not Completed | 2 (8.0%) | 1 (5.9%) | 0 (0.0%) | 0 (0.0%) | 3 (3.0%) |

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

**MTN 042 - DELIVER: A Phase 3b Safety Study of the Dapivirine Ring and PrEP in Pregnant Women
Data as of December 1, 2025**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up¹ by Site - Infants Cohort 3

| | Malawi Blantyre | SA Shandukani | Uganda Kampala | Zimbabwe Zengeza | All Sites |
|---|----------------------------|--------------------------|---------------------------|-----------------------------|------------------|
| Participants Enrolled | 66 | 40 | 67 | 72 | 245 |
| 1. Physical Exam Required and Expected | 260 | 136 | 264 | 272 | 932 |
| Completed | 260 (100.0%) | 135 (99.3%) | 263 (99.6%) | 272 (100.0%) | 930 (99.8%) |
| Not Completed | 0 (0.0%) | 1 (0.7%) | 1 (0.4%) | 0 (0.0%) | 2 (0.2%) |
| 2. Creatinine Required and Expected | 130 | 65 | 132 | 137 | 464 |
| Completed | 129 (99.2%) | 65 (100.0%) | 131 (99.2%) | 135 (98.5%) | 460 (99.1%) |
| Not Completed | 1 (0.8%) | 0 (0.0%) | 1 (0.8%) | 2 (1.5%) | 4 (0.9%) |
| 3. Dried Blood Spot for TFV-DP and FTC-TP drug levels Required and Expected (Truvada group only) | 13 | 6 | 13 | 13 | 45 |
| Completed | 12 (92.3%) | 6 (100.0%) | 13 (100.0%) | 13 (100.0%) | 44 (97.8%) |
| Not Completed | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (2.2%) |
| 4. Plasma for DPV Drug levels Required and Expected (DPV group ony) | 52 | 26 | 53 | 54 | 185 |
| Completed | 50 (96.2%) | 26 (100.0%) | 53 (100.0%) | 54 (100.0%) | 183 (98.9%) |
| Not Completed | 2 (3.8%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (1.1%) |

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit. If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.